Volition

Volition Appoints DXOCRO to Spearhead U.S. FDA Strategy

Retrieved on: 
Monday, August 8, 2022
FDA, U.S. Securities and Exchange Commission, Drug Quality and Security Act, Quality, Laboratory, Forward-looking statement, NYSE, Failure, Technology, Securities Exchange Act of 1934, Cancer, Disease, LLC, Security (finance), Research, Annual report, Life, Marketing, Neutrophil extracellular traps, Volition (linguistics), Patient, Quality of life, COVID-19, State, Biotechnology, NETS, Sepsis, IVD, Securities Act of 1933, Science, Human, Animal, Development, Medical device, Volition, Nucleosome

They are an ideal partner for us as we develop our FDA strategy in the United States.

Key Points: 
  • They are an ideal partner for us as we develop our FDA strategy in the United States.
  • "DXOCRO will spearhead both our clinical product development and our regulatory program in the United States, and seek to establish clinical utility for our Nu.Q products.
  • Through the conduct of Volition's clinical validation studies, we hope to validate a broad range of potential Nu.Q products and support Volition's U.S. commercialization strategy."
  • Volition is primarily focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.

VolitionRx Awarded $1.5 Million in Non-Dilutive Funding

Retrieved on: 
Wednesday, August 3, 2022
Failure, Human, Securities Act of 1933, Diagnosis, Security (finance), Annual report, COVID-19, Quality of life, Internet, Life, Wallonia, NYSE, Securities Exchange Act of 1934, Patient, U.S. Securities and Exchange Commission, Cancer, Volition (linguistics), Animal, Disease, Neutrophil extracellular traps, Technology, Research, Science, Forward-looking statement, Adoption, Sepsis, Pharmaceutical industry, Medical device, EU, Nucleosome, Volition

HENDERSON, Nev., Aug. 3, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has announced it has been awarded a further $1.5 million non-dilutive funding from Namur Invest Capital Risk in Belgium.

Key Points: 
  • HENDERSON, Nev., Aug. 3, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has announced it has been awarded a further $1.5 million non-dilutive funding from Namur Invest Capital Risk in Belgium.
  • "We will be working with centers of excellence worldwide providing leading clinicians and researchers with exclusive, early access to our Nu.Q product range.
  • Namur Invest's loan is the latest grant from agencies within the Walloon Region, amounting to more than $14 million in non-dilutive funding since 2016.
  • Nucleosomics and Nu.Q and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries.

Salarius Pharmaceuticals and VolitionRx Enter into R&D Collaboration Agreement

Retrieved on: 
Tuesday, August 2, 2022
Gene expression, Research institute, GLOBE, Food and Drug Administration, U.S. Securities and Exchange Commission, Twitter, Human, Food, Trial of the century, Sarcoma, NYSE, SEC, Research, Biomarker, Sepsis, Private Securities Litigation Reform Act, Neutrophil extracellular traps, COVID-19, NASDAQ, Cancer, HIV disease progression rates, Quality of life, MD Anderson Cancer Center, Clinical trial, LSD1, Ewing's sarcoma, Disease, Drug development, Patient, LinkedIn, Science, Life, Biology, Annual report, Animal, Investor, Hematological Cancer Research Investment and Education Act, Pharmaceutical industry, Salinicola salarius, Volition, Nucleosome

So, this exciting research collaboration with Volition Rx Limited provides another tool to aid in the development of seclidemstat in clinic.

Key Points: 
  • So, this exciting research collaboration with Volition Rx Limited provides another tool to aid in the development of seclidemstat in clinic.
  • We are looking forward to supporting Salarius in the development and release of their groundbreaking seclidemstat therapy, to directly benefit patients with cancer.
  • Salarius Pharmaceuticals, Inc.is a clinical-stage biopharmaceutical company developing therapies for patients with cancer in need of new treatment options.
  • Salarius may not actually achieve the plans, carry out the intentions or meet the expectations or objectives disclosed in the forward-looking statements.

VolitionRx Limited Announces Pricing of $6 Million Underwritten Public Offering of Common Stock

Retrieved on: 
Friday, July 29, 2022
Sale, U.S. Securities and Exchange Commission, Forward-looking statement, NYSE, SEC, Research, Telephone, Risk, SEC filing, Sepsis, Securities Act of 1933, Securities Exchange Act of 1934, Neutrophil extracellular traps, COVID-19, Prospectus, Volition, Quality of life, Attention, Disease, Company, Science, Cancer, Patient, Security (finance), Life, Annual report, Volition (company), Suite, Form, Nucleosome

HENDERSON, Nev., July 29, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announced today the pricing of its underwritten public offering of 3,000,000 shares of its common stock at a public offering price of $2.00 per share.

Key Points: 
  • HENDERSON, Nev., July 29, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announced today the pricing of its underwritten public offering of 3,000,000 shares of its common stock at a public offering price of $2.00 per share.
  • The gross proceeds to Volition from the offering, before deducting the underwriting commissions and other estimated offering expenses payable by Volition, are expected to be $6 million.
  • The offering is expected to close on or about August 2, 2022, subject to the satisfaction of customary closing conditions.
  • Nucleosomics and Nu.Q and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries.

VolitionRx Limited Announces Proposed Underwritten Public Offering of Common Stock

Retrieved on: 
Thursday, July 28, 2022
Sale, U.S. Securities and Exchange Commission, NYSE, SEC, SEC filing, Research, Telephone, Royal Securities Corporation, Sepsis, Neutrophil extracellular traps, COVID-19, Prospectus, Volition, Quality of life, Attention, Disease, Company, Science, Cancer, Patient, Security (finance), Life, Suite, Form, Nucleosome

HENDERSON, Nev., July 28, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announced today that it has commenced an underwritten public offering of its common stock.

Key Points: 
  • HENDERSON, Nev., July 28, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announced today that it has commenced an underwritten public offering of its common stock.
  • All of the shares of common stock are being offered by Volition.
  • In addition, Volition intends to grant the underwriter in the offering a 30-day option to purchase up to an additional 15% of the number of shares of common stock offered in the offering at the public offering price, less underwriting discounts and commissions.
  • The final terms of the proposed offering will depend on market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Volition Capital Vice President Claude de Jocas Named a 2022 Top Women Leader in Growth Investing

Retrieved on: 
Wednesday, July 20, 2022
Harvard Business School, Investment, Human, Consumer, Twitter, Female, Woman, Environmental studies, Software, BA, Beauty, Leadership, US Mobile Tolling Platforms, Technology, MBA, Chief executive officer, Centre for Socio-economic and Environmental Studies, Peloton, Internet, Financial services, Management, Yale University, Economics, Volition

BOSTON, July 20, 2022 /PRNewswire-PRWeb/ -- Volition Capital, a leading technology and consumer growth equity firm, today announced that Claude de Jocas has been recognized as one of The Top Women Leaders in Growth Investing of 2022 by GrowthCap.

Key Points: 
  • Chosen from a competitive pool of female leaders, de Jocas is recognized for her commitment to her portfolio companies, her outstanding leadership at Volition Capital, and her dedication to innovation in the venture capital and growth equity space at large.
  • "More often than not, when it is time to raise capital, women are left out of the conversation," said de Jocas.
  • de Jocas joined Volition Capital in 2019 and is a Vice President on the Internet and Consumer investment team.
  • Volition Capital is a Boston-based growth equity firm that principally invests in high-growth, founder-owned companies across the software, Internet, and consumer sectors.

Gebrüder Weiss Expands International Bicycle Campaign After Goal to Circle the Globe Reached in 45 Days

Retrieved on: 
Wednesday, June 15, 2022
Weiss, Volition, Communication, Tree, History, GLOBE, Road, Earth

The original aim was to cycle a total distance of 40,075 kilometers throughout the campaign - the same as the length of the equator.

Key Points: 
  • The original aim was to cycle a total distance of 40,075 kilometers throughout the campaign - the same as the length of the equator.
  • The campaign goal was reached just 45 days after it began.
  • The Earth was circled for a second time in mid-June, so Gebrder Weiss set a new goal: to circle the Earth for a third time, covering a total of 120,225 kilometers.
  • Still, we never thought they would manage it so quickly," says Frank Haas, Head of Corporate Brand Strategy & Communications at Gebrder Weiss.

DGAP-News: Rational to begin controlled exit from Russian market

Retrieved on: 
Tuesday, June 7, 2022
Leadership, DGAP, Food, MDAX, International sanctions during the Ukrainian crisis, Social responsibility, News, CEO, Face, Technology, Volition, Supervisory board, Rationality, Board of directors, Safety, Security (finance), Online gambling, Risk management, Public relations

Rational has made this decision in response to the economic and political developments resulting from the Russian war in Ukraine.

Key Points: 
  • Rational has made this decision in response to the economic and political developments resulting from the Russian war in Ukraine.
  • The company's withdrawal will be gradual and controlled so that it can continue to meet existing customer and employee obligations.
  • At the beginning of March 2022, Rational acted of its own volition to suspend the delivery of cooking systems to Russia.
  • In terms of financial implications, Rational is confident that losing the Russian market will not have a significant impact on business results.

Arteza Launches Fuel Your Creativity Campaign to Empower Artists & Pave a Path for Digital Creativity

Retrieved on: 
Wednesday, June 1, 2022
United Kingdom, Life, Human, Non-fungible token, Spiro, Beauty, Wolf, CEO, Volition, YouTube, Sale, Fuel, Creativity, Twitter, Industry, Collection, Wynwood, Painting, Revenue, TikTok, Education, Hatmaking, Video game, Creative industries, Interior design, Facebook, Instagram

MIAMI, June 1, 2022 /PRNewswire/ -- Arteza, a rapidly scaling arts and crafts brand dedicated to championing the art community by providing premium yet affordable products and a personalized customer experience, today announced the launch of its pivotal campaign, Fuel Your Creativity. The Fuel Your Creativity campaign will redefine what it means to be an artist as it aims to transform a traditional industry and empower creators by paving a path for artistic inspiration, education, and digital creativity.

Key Points: 
  • The Fuel Your Creativity campaign will redefine what it means to be an artist as it aims to transform a traditional industry and empower creators by paving a path for artistic inspiration, education, and digital creativity.
  • "We are putting seven "gate-crashing" artists front and center of our Fuel Your Creativity campaign.
  • Driven by seven global artists, Fuel Your Creativity will connect and empower budding artists around the world with its thumb-stopping content.
  • For more information on the Fuel Your Creativity NFT Collection, you can visit the Fuel Your Creativity Rarible Marketplace page .

Verano Prevails in Nielsen Arbitration Dismissing All Claims

Retrieved on: 
Monday, May 23, 2022
Employment, Knowledge, Nielsen, Prejudice, RICO, Federal court, CSE, Complaint, Compliance, Racketeer Influenced and Corrupt Organizations Act, Douglas v. U.S. District Court ex rel Talk America, Volition, LLC, District court, District, GLOBE, Drug

CHICAGO, May 23, 2022 (GLOBE NEWSWIRE) -- Verano Holdings Corp. (CSE: VRNO) (OTCQX: VRNOF) (Verano or the Company), through its subsidiary, Verano Holdings, LLC, yesterday notified the U.S. District Court for the District of Colorado of its complete victory in arbitration regarding various frivolous RICO (Racketeer Influenced and Corrupt Organizations Act) claims brought by Nicholas Nielsen.

Key Points: 
  • CHICAGO, May 23, 2022 (GLOBE NEWSWIRE) -- Verano Holdings Corp. (CSE: VRNO) (OTCQX: VRNOF) (Verano or the Company), through its subsidiary, Verano Holdings, LLC, yesterday notified the U.S. District Court for the District of Colorado of its complete victory in arbitration regarding various frivolous RICO (Racketeer Influenced and Corrupt Organizations Act) claims brought by Nicholas Nielsen.
  • The arbitrator dismissed all of Nielsens claims with prejudice and awarded Verano nearly $100,000 in attorneys fees in the arbitration, further underscoring the groundless nature of the lawsuit.
  • The allegations in the complaint are completely and totally false and absurd, said George Archos, Verano Founder and Chief Executive Officer.
  • With operations in 13 states, all with highly regulated state-legalized cannabis programs, Verano is a leading, vertically integrated multi-state cannabis operator in the United States.